🌟 We owe it all to YOU, our amazing followers! 🌟 As we reflect on our journey, we're grateful for your unwavering support through the years. Your likes, comments, and shares have fueled our growth and inspired us to reach new heights. Let’s stay connected! We invite you to join us at TriNetX to continue this incredible journey together. There, you'll find updates, news, and insights from our team and extended colleagues. Thank you once again for being a part of our community. Here's to many more milestones together!
OncologyInformationService (acquired by TriNetX)
Biotechnologieforschung
Acquired by TriNetX, LLC.
Info
OncologyInformationService is now TriNetX Oncology GmbH! TriNetX Oncology GmbH is a wholly owned subsidiary of TriNetX, LLC. For the latest updates, follow our Enterprise LinkedIn Company Page: https://www.linkedin.com/company/trinetx/ In the last 25 years we have established a unique position in the European oncological area, providing a broad range of real-world services tailor-made for HEOR, marketing and medicine in oncology/haematology. Our strengths: • High level knowledge in this treatment area, almost all manufacturers in this area as long term clients • Comprehensive and updated directory of target population in oncology/haematology, covering not only Key European Countries, but even Russia • An international reputation based on publications in ASCO, ASH, ISPOR and other conventions or in peer-reviewed journals. • Disease-specific RWE (Therapy Monitor), offering data for a large patient sample generated from a representative sample of specialties/institutions in each country. • High standards in quality management • Health economic data and analysis • Comprehensive data analysis with advanced explorative statistic methods • Visualisation of results in interactive dashboards • Approved in vendor audits • Our own international team of project managers and interviewers, most of them native speakers. Our interviewers are all medically trained and many of them have a medical background.
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Freiburg
- Art
- Privatunternehmen
- Gegründet
- 1993
- Spezialgebiete
- Real World Data, Healthcare Research, Market Research, Oncology, Hematology, PatientReportedOutcomes, Worldwide Studies, European Focus, OncoRegioPanel (ORP), TherapyMonitor (TM) und Real World Evidence
Orte
-
Primär
Wegbeschreibung
Freiburg, DE
Beschäftigte von OncologyInformationService (acquired by TriNetX)
-
Lenka Kellermann
Ex - Senior Vice President Oncology, Managing Director at TriNetX Oncology GmbH, retired; WiDS Catalyst Advisor
-
Victoria Smith-Machnow
Head of Project Management at Trinetx Oncology GmbH
-
Stefan Schilling
Head of Data Operations at TriNetX Oncology GmbH
-
Alexander Pries
Clinical Monitor at TriNetX
Updates
-
Do you find Zuzana Dostálová, @Danial Kamran and Guillaume Azarias among the CERTAINTY united team at the kick-off-meeting in Leipzig?
In 2023, we united to design a visionary project and won funding through a competitive process. Today, we're in Leipzig, Germany, at Fraunhofer IZI for our first in-person kick-off! With 4.5 years ahead, we're ready to embark on this exciting journey. #CERTAINTYVirtualTwin #KickOff #FraunhoferIZI #Leipzig
-
-
We are so proud of Danial Kamran as a part of our fabulous team of Data Scientists! He has been working in parallel unbelievably hard on multiple challenging projects and has never lost his great positive spirit. Congratulations 🎉🎈🎊
Dr.-Ing. Danial Kamran hat seine Doktorarbeit mit dem Titel "Generalized Reinforcement Learning for Automated Driving under Uncertainty" erfolgreich verteidigt. In seiner Dissertation nutzte er Reinforcement Learning um menschenähnliche Verhaltensentscheidungen für das autonome Fahren unter Unsicherheit zu modellieren. Durch das Einbeziehen von Sicherheit, Skalierbarkeit, und Generalisierbarkeit, stellt er sicher, dass seine Methode auf verschiedene reale Szenarien anwendbar ist. Seine Dissertation wurde von Prof. Dr.-Ing. Christoph Stiller (Karlsruher Institut für Technologie) und Prof. Dr. Matthijs Spaan (Technische Universität Delft) betreut. Das MRT gratuliert herzlich und wünscht Danial alles Gute!
-
-
OncologyInformationService (acquired by TriNetX) hat dies direkt geteilt
Our team of analysts, epidemiologists, and evidence strategists represent decades of world-class training and experience. Partner with TriNetX to uncover solutions to your research challenges. Learn more: https://ow.ly/x4Uk50QIVLs #RealWorldEvidence #HealthcareInnovation
-
-
TWE Solutions market is boosting! We are the only provider with a deep knowledge and engagement in a specific therapeutic area: Oncology & Hematology are our passion!
𝗥𝗲𝗮𝗹 𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗪𝗼𝗿𝘁𝗵 $𝟰.𝟱 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟮𝟵 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/d5vtjCKD The global real world evidence solutions market in terms of revenue was estimated to be worth $2.0 Billion in 2024 and is poised to reach $4.5 Billion by 2029, growing at a CAGR of 16.5% from 2024 to 2029. Prominent players in real-world evidence solutions markt include IQVIA, Merative, Optum, ICON plc., Syneos Health, PAREXEL International (UK) Limited, Elevance Health, SAS Institute, Aetion, TriNetX Oncology GmbH, Trinity Health (US), PerkinElmer, Cognizant, Clinigen, Cegedim Health Data, Verantos (US), HealthVerity, Datavant (US), Syapse, Inc. (US), Tempus AI (US), Flatiron Health (US), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (US), Oracle (US), and MedSpace.
-